RxDoctor Payments Data

Ann Parker

Family · Bowie, MDNPI 1588965784

Payments from drug & device makers

$2,019in general payments, 2019–2025

Across 65 payments — averaging $31.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Veloxis Pharmaceuticals, Inc.$378
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$340
  • AbbVie$275
  • Mallinckrodt Hospital Products Inc.$183
  • Gilead$160
  • Takeda Pharmaceuticals U.S.A., Inc.$144
  • plus $538 from 12 others

What the payments were for

  • Food & beverage$2,019100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,019 in reported general payments places this provider in the 80th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$822
Medicare patients
11
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$22,387
Cinacalcet Hcl50$13,273
FarxigaDapagliflozin Propanediol11$6,299
Clonidine18$2,171
Tamsulosin Hcl89$1,961
Labetalol Hcl39$1,683
Pantoprazole Sodium117$1,445
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates23$1,392
Nifedipine ErNifedipine37$1,178
Prednisone174$944
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$884
Amlodipine Besylate86$708
Atorvastatin Calcium81$688
Calcitriol34$624
Carvedilol66$548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$82$6,29911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,843 family providers in Maryland.

Other family in Bowie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →